Dr Thomas Massey
Prosiectau fel Prif Ymchwiliwr
- Consultation on the exploitation relating to drug discovery and biomarker development focused on targeting aberrant DNA damage repair to treat neurodegenerative trinucleotide repeat expansion discovery (01.10.2019 - 30.09.2023)
- Identification of coding variants in DNA repair genes affecting age at onset of Huntington's disease (01.08.2016 - 31.10.2017)
- Investigating the effects of GAG repeat structure and MSH3 variants on the molecular biology of Huntington's disease (01.08.2018 - 31.12.2019)
- The role of DNA repair in Huntington's disease pathogenesis: Towards new therapeutic targets (01.08.2016 - 31.07.2019)
- The role of DNA repair in Huntington's disease pathogenesis: towards novel therapeutic targets (01.10.2016 - 30.09.2021)
Prosiectau fel Cyd-Ymchwiliwr
- One-week exercise training induces white matter microstructural and blood flow changes: a multi-modal MRI study (01.01.2017 - 31.12.2017)
- A high content analysis platform for analysing dementia-associated genetic variation (10.03.2017 - 09.09.2017)
- An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139 (17.04.2018 - 30.04.2020)
- Characterising Genetic Modifiers of Huntington's Disease (01.10.2021 - 30.04.2024)
- Consultation on the exploitation relating to drug discovery and biomarker development focused on targeting aberrant DNA damage repair to treat neurodegenerative trinucleotide repeat expansion discovery (04.10.2019 - 03.10.2023)